Clinical trials: Hodgkin´s Lymphoma
Hodgkin´s Lymphoma
HD11 for Intermediate Stages
This study is designed to (1) compare the efficacy of the BEACOPP regimen with that of ABVD as a 4-cycle chemotherapy combined with an involved field irradiation and (2) to define the optimum radiation dose comparing of 30 to 20…
- Trial name
- NCT00264953
- Testing
- Adriamycin, Bleomycin, Vinblastine
- Volunteers
- 1,395 people
- Sponsor
- University of Cologne
Hodgkin Lymphoma
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma
Hodgkin's Lymphoma (HL) is a neoplasm that affects the lymph nodes and the lymphatic system. In Mexico, HL is the seventh most incident cancer and the ninth with the highest mortality.
- Trial name
- NCT05490953
- Testing
- Pentoxifylline
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- University of Guadalajara
Non-Hodgkin's Lymphoma
Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)
The purpose of this trial is to investigate the clinical benefit of the dose intensified regimen, Bi-CHOP in comparison to standard CHOP for advanced intermediate or high grade non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT00133302
- Testing
- Standard CHOP, Bi-CHOP (dose intensified CHOP)
- Where
- Japan
- Volunteers
- 450 people
- Sponsor
- Japan Clinical Oncology Group
Hodgkin´s Lymphoma
HD12 for Advanced Stages
This study is designed to test (1) whether the BEACOPP dosage can be reduced to baseline in the last 4 cycles without loss of effectiveness, and (2) whether consolidating irradiation is necessary following effective chemotherapy.
- Trial name
- NCT00265031
- Testing
- Cyclophosphamide, Adriamycin, Etoposide
- Sponsor
- University of Cologne
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL
This study aims to investigate a novel therapeutic strategy of integrated radiotherapy before autologous stem cell transplantation (ASCT) sequential chimeric antigen receptor T-cell(CAR-T) therapy for patients with…
- Trial name
- NCT07059741
- Testing
- integrated low-dose RT with reduced SEAM/TB conditioning before ASCT sequential CAR-T, integrated high-dose RT with reduced SEAM/TB conditioning before ASCT sequential CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Hodgkin´s Lymphoma
HD10 for Early Stages
This study is designed to find the optimum radiation dose and number of cycles for an ABVD chemotherapy combined with an involved field irradiation.
- Trial name
- NCT00265018
- Testing
- Adriamycin, Bleomycin, Vinblastine
- Volunteers
- 1,370 people
- Sponsor
- University of Cologne
B-cell Non-Hodgkin Lymphoma
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
This is a phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with relapsed/refractory B-cell non-Hodgkin…
- Trial name
- Lumi-NHL (NCT07123454)
- Testing
- AZD4512, Surovatamig
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 164 people
- Sponsor
- AstraZeneca
Follicular Lymphoma, Follicular Non-Hodgkin´s Lymphoma
Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy
Nowadays, therapy with monoclonal antibodies is considered to be a standard treatment that increases the rate of remissions and the overall survival in patients with follicular lymphoma.
- Conditions
- Follicular Lymphoma, Follicular Non-Hodgkin´s Lymphoma, Autologous Effector Lymphocytes
- Trial name
- NCT01329354
- Testing
- Autologous effector lymphocytes expanded ex-vivo
- Where
- Spain
- Volunteers
- 38 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
B-cell Acute Lymphoblastic Leukemia (B-ALL)
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
- Trial name
- ALLight (NCT07109219)
- Testing
- AZD4512 monotherapy
- Where
- 27 sites in United States, Australia and 7 more
- Volunteers
- 83 people
- Sponsor
- AstraZeneca
Myeloma, Non Hodgkin's Lymphoma
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)
This study is being conducted to find out how safe and effective different strategies of infection prevention are in comparison to each other, for preventing infection in patients with blood cancers.
- Conditions
- Myeloma, Non Hodgkin's Lymphoma, Leukemia
- Trial name
- NCT07202078
- Testing
- Trimethoprim / Sulfamethoxazole, Immune Globulin Intravenous
- Where
- 3 sites in Australia
- Volunteers
- 900 people
- Sponsor
- Monash University